Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad
开发非抗凝重组肝素治疗慢性阻塞性肺病致病三联征
基本信息
- 批准号:10382108
- 负责人:
- 金额:$ 32.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-05 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAlveolarAnimal ModelAnti-Inflammatory AgentsAnticoagulantsAnticoagulationAntioxidantsBindingBiochemicalBiological AssayBloodBreathingCaliforniaCause of DeathCell LineCellsCessation of lifeChargeChronicChronic Obstructive Pulmonary DiseaseChronic lung diseaseClinicClinicalCollaborationsConsultCystic FibrosisDevelopmentDiseaseDisease ProgressionDoseDrug KineticsDustElastasesElectrostaticsEndothelial Growth Factors ReceptorExposure toFeasibility StudiesFormulationGenetic EngineeringGoalsHealthcareHeparinHeparitin SulfateHeparitin sulfotransferaseHumanIn VitroInflammationInflammation MediatorsInhalationInhalation ExposureInhalation TherapyInjectionsLifeLungMammalian CellMast Cell NeoplasmModelingOccupationalOxidative StressPathogenicityPatientsPeptide HydrolasesPharmaceutical PreparationsPhasePopulationPrevalenceProductionPropertyProteinsPulmonary EmphysemaQuality of lifeRattusRecombinantsSU 5416SeriesSputumSulfateTechnologyTestingTherapeuticTherapeutic InterventionTherapeutic UsesToxicologyTreatment EfficacyTriad Acrylic ResinUniversitiesVEGFA geneVirginiaWorkalpha 1-Antitrypsin Deficiencyantagonistbasebioprocesscellular engineeringcigarette smokecigarette smokingcytokinedrug developmenteffective therapyelastase inhibitorfunctional disabilityimprovedin vivoin vivo evaluationinhibitorinterestnovelnovel strategiesoverexpressionpalliativepreventsmoking exposuresuccesstargeted treatment
项目摘要
PROJECT SUMMARY
This proposal describes a novel strategy to treat emphysema in COPD (chronic obstructive pulmonary
disease) using uniquely tailored heparan sulfate produced from genetically engineered mammalian cells.
Emphysema is a major component of COPD, a disease that afflicts up to 5% of the population and is the 4th
leading cause of death in the US. There is currently no drug that has proven efficacious to cure or delay
progression of the disease. While targeted therapies have shown little clinical benefit, heparin has multi-point
inhibitory activity against the three major drivers of disease progression (proteases, oxidative stress and
inflammation) and can be inhaled for local treatment. Heparin’s usefulness is limited by its anticoagulant
activity. TEGA Therapeutics’ recombinant heparan sulfate production technology enables targeted elimination
of 3-O-sulfate groups that are essential for anticoagulant activity while maintaining anti-elastolytic, anti-
oxidative and anti-inflammatory properties. Mammalian cell lines that produce heparan sulfate without 3-O-
sulfate will be genetically engineered to improve inhibition of emphysema drivers. The products will then be
tested to evaluate their ability to inhibit proteases, oxidative stress and inflammatory mediators in vitro. Finally,
the efficacy of the top candidate will be assessed through orotracheal delivery in a rat model of emphysema.
The resulting product will be further developed as an inhalable drug in Phase II through bioprocess
development, formulation, toxicology studies and pharmacokinetic studies. Success in this endeavor will yield
a clinical drug that limits the progression of emphysema and increases the duration and quality of life for
patients. It would likely also be useful for other chronic pulmonary diseases including cystic fibrosis and alpha-
1 antitrypsin deficiency.
项目摘要
该提案描述了一种治疗COPD(慢性阻塞性肺疾病)肺气肿的新策略
疾病),使用由基因工程哺乳动物细胞产生的独特定制的硫酸乙酰肝素。
肺气肿是慢性阻塞性肺病的主要组成部分,慢性阻塞性肺病是一种折磨高达5%的人口的疾病,
美国的主要死因。目前还没有一种药物已被证明有效治愈或延迟
疾病的进展。虽然靶向治疗几乎没有显示出临床益处,但肝素具有多点作用,
对疾病进展的三个主要驱动因素(蛋白酶、氧化应激和
炎症),并且可以吸入用于局部治疗。肝素的作用受到其抗凝剂的限制
活动TEGA Therapeutics的重组硫酸乙酰肝素生产技术可实现靶向消除
3-O-硫酸基团,是必不可少的抗凝活性,同时保持抗弹性蛋白溶解,抗
氧化和抗炎特性。产生硫酸乙酰肝素而不含3-O-的哺乳动物细胞系
硫酸盐将被基因工程化以改善对肺气肿驱动因子的抑制。产品将在
测试以评估它们在体外抑制蛋白酶、氧化应激和炎症介质的能力。最后,
通过在肺气肿大鼠模型中经口气管递送来评估最佳候选物的功效。
所得产品将在第二阶段通过生物工艺进一步开发为可吸入药物
开发、制剂、毒理学研究和药代动力学研究。这一奋进的成功将产生
一种临床药物,可限制肺气肿的进展,并增加持续时间和生活质量,
患者它可能也适用于其他慢性肺部疾病,包括囊性纤维化和α-
1例抗胰蛋白酶缺乏。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Alexander Glass其他文献
Charles Alexander Glass的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Alexander Glass', 18)}}的其他基金
Inhibitors of Heparan Sulfate Biosynthesis and Cancer
硫酸乙酰肝素生物合成抑制剂与癌症
- 批准号:
7110737 - 财政年份:2006
- 资助金额:
$ 32.19万 - 项目类别:
Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs
神经再生药物的硫酸软骨素抑制剂筛选
- 批准号:
7154308 - 财政年份:2006
- 资助金额:
$ 32.19万 - 项目类别:
相似海外基金
Gain-of-function toxicity in alpha-1 antitrypsin deficient type 2 alveolar epithelial cells
α-1 抗胰蛋白酶缺陷型 2 型肺泡上皮细胞的功能获得毒性
- 批准号:
10751760 - 财政年份:2024
- 资助金额:
$ 32.19万 - 项目类别:
The role of alveolar macrophages and regulatory pathways in post-transplant lung inflammation.
肺泡巨噬细胞和调节途径在移植后肺部炎症中的作用。
- 批准号:
23K08315 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pilot Studies of PAX3-FOXO1 Fusions Proteins in Alveolar Rhabdomyosarcoma
PAX3-FOXO1 融合蛋白在肺泡横纹肌肉瘤中的初步研究
- 批准号:
10726763 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells
桥粒斑蛋白对肺泡2型细胞肺纤维化的遗传贡献机制研究
- 批准号:
10736228 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis
利用诱导多能干细胞研究肺泡2型细胞功能障碍在肺纤维化中的作用
- 批准号:
10591174 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome
肝肺综合征低氧血症的新肺泡机制
- 批准号:
10718446 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Mechanical signaling through the nuclear membrane in lung alveolar health
通过核膜的机械信号传导影响肺泡健康
- 批准号:
10677169 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Injury of blood brain and alveolar-endothelial barriers caused by alcohol and electronic cigarettes via purinergic receptor signaling
酒精和电子烟通过嘌呤受体信号传导引起血脑和肺泡内皮屏障损伤
- 批准号:
10638221 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Alveolar Epithelial Cell Dysfunction Induced By Flavored E-Cigarette Aerosols
加味电子烟气雾剂引起的肺泡上皮细胞功能障碍
- 批准号:
10770080 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Delineating the role of let-7 microRNA on lung AT2 cell homeostasis, alveolar regeneration, and interstitial lung disease
描述let-7 microRNA对肺AT2细胞稳态、肺泡再生和间质性肺疾病的作用
- 批准号:
10634881 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别: